Toth Financial Advisory Corp boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 3.3% during the second quarter, according to its most recent filing with the SEC. The firm owned 24,261 shares of the medical instruments supplier’s stock after buying an additional 783 shares during the period. Toth Financial Advisory Corp’s holdings in Becton, Dickinson and were worth $4,734,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in BDX. North Star Investment Management Corp. boosted its position in shares of Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock worth $101,000 after buying an additional 18 shares during the period. Crestwood Advisors Group LLC purchased a new position in shares of Becton, Dickinson and during the first quarter worth about $101,000. Almanack Investment Partners LLC. purchased a new position in shares of Becton, Dickinson and during the first quarter worth about $105,000. Parkside Financial Bank & Trust boosted its position in shares of Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 9 shares during the period. Finally, Financial Architects Inc boosted its position in shares of Becton, Dickinson and by 62.7% in the first quarter. Financial Architects Inc now owns 677 shares of the medical instruments supplier’s stock worth $124,000 after buying an additional 261 shares during the period. 75.57% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company (BDX) traded up 0.32% during mid-day trading on Monday, hitting $198.33. 209,935 shares of the company’s stock were exchanged. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $206.63. The stock has a market cap of $45.13 billion, a PE ratio of 57.44 and a beta of 1.05. The stock’s 50 day moving average price is $199.72 and its 200-day moving average price is $188.69.

Becton, Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. During the same period in the previous year, the business posted $2.35 earnings per share. The business’s revenue for the quarter was down 5.1% on a year-over-year basis. Equities analysts expect that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 8th will be paid a $0.73 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.48%. Becton, Dickinson and’s dividend payout ratio is presently 83.43%.

TRADEMARK VIOLATION NOTICE: This piece of content was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/21/becton-dickinson-and-company-bdx-position-raised-by-toth-financial-advisory-corp.html.

A number of research analysts recently issued reports on the stock. Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Cowen and Company reissued a “buy” rating and issued a $230.00 price objective on shares of Becton, Dickinson and in a research note on Monday, August 14th. Barclays PLC reissued an “equal weight” rating and issued a $210.00 price objective (up from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. BidaskClub raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Finally, Zacks Investment Research cut shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Monday, August 7th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $195.79.

In other news, insider Nabil Shabshab sold 6,149 shares of Becton, Dickinson and stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $201.76, for a total value of $1,240,622.24. Following the completion of the sale, the insider now directly owns 15,648 shares in the company, valued at $3,157,140.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Ellen R. Strahlman sold 9,283 shares of Becton, Dickinson and stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the completion of the sale, the insider now owns 26,638 shares of the company’s stock, valued at $5,279,917.98. The disclosure for this sale can be found here. Insiders sold 57,631 shares of company stock valued at $11,112,178 over the last quarter. Company insiders own 1.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.